Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation

NCT03529825 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT03529825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03529825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation
Lead sponsor
Emory University
Phase
Phase 1
Overall status
Completed
Start date
July 18, 2018
Completion date
September 10, 2021
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

microbial colonization